A study reveals declining US neonatal mortality overall, yet highlights rising deaths from fetal malnutrition, emphasizing ongoing disparities in neonatal health outcomes.

Data from the study suggest caretakers of CPP patients be vigilant for psychiatric symptoms to begin care at an early stage. There was evidence of an elevated risk for psychiatric disorders among ...

Even low-level lead exposure in early childhood may speed up memory loss, according to a new study using a cognitive task to measure forgetting rates.

The FDA accepted Eton Pharmaceuticals' NDA for ET-600 for pediatric arginine vasopressin deficiency, with a target action date in February of 2026.

On July 7, 2025, the FDA approved KalVista Pharmaceuticals' novel plasma kallikrein inhibitor sebetralstat (Ekterly) to treat acute attacks of hereditary angioedema (HAE) in adult and pediatric ...

Multiple medical societies, including the American Academy of Pediatrics (AAP), are suing the US Department of Health and Human Services (HHS) and Secretary Robert F. Kennedy Jr. in an effort to ...

A newly-published study identified specific groups of higher-risk children that could benefit most from monoclonal antibodies.

View our Q2 2025 recap of standout pediatric news from FDA regulatory updates, clinical trial results, and expert commentary.

A week into July 2025, the total reported cases in the United States have surpassed the peak of 1274 cases recorded for all 2019. As of July 4, 2025, there were 1277 measles cases reported in the ...

A look back at the most important FDA approvals, clinical research, and expert perspectives shaping pediatric health care in the first half of 2025.

A roundup of the most impactful FDA approvals in pediatric health from January through June 2025, spanning diagnostics, therapeutics, and at-home care.

The revised labeling will warn that patients younger than 6 years taking these medications are at greater risk of weight loss.